Pro-red
NDC 66594-499
Product Information
Pro-red is a OTC MONOGRAPH FINAL-approved product labeled by Pro-pharma, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 66594-499 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 66594-499?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CODEINE PHOSPHATE (UNII: GSL05Y1MN6)
- CODEINE ANHYDROUS (UNII: UX6OWY2V7J) (Active Moiety)
- DEXCHLORPHENIRAMINE MALEATE (UNII: B10YD955QW)
- DEXCHLORPHENIRAMINE (UNII: 3Q9Q0B929N) (Active Moiety)
- PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ)
- PHENYLEPHRINE (UNII: 1WS297W6MV) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- GLYCERIN (UNII: PDC6A3C0OX)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- WATER (UNII: 059QF0KO0R)
- SODIUM CITRATE (UNII: 1Q73Q2JULR)
- SACCHARIN SODIUM (UNII: SB8ZUX40TY)
- SORBITOL (UNII: 506T60A25R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1440003 - codeine phosphate 9 MG / dexchlorpheniramine maleate 1 MG / phenylephrine HCl 5 MG in 5 mL Oral Solution
- RxCUI: 1440003 - codeine phosphate 1.8 MG/ML / dexchlorpheniramine maleate 0.2 MG/ML / phenylephrine hydrochloride 1 MG/ML Oral Solution
- RxCUI: 1440003 - codeine phosphate 9 MG / dexchlorpheniramine maleate 1 MG / phenylephrine hydrochloride 5 MG per 5 ML Oral Solution
* Please review the full disclaimer at the bottom of this page.